RNS Announcements

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its audited results for the period ended 31 December 2024.

Key Highlights

• Sales +13% to £1.883m (2023: £1.673m)
• Gross Profit +14% to £997k (2023: £872k)
• Gross Profit margin robust at 53% (2023: 52%)
• Solid financial position with cash balances totalling £1.65m (2023: £1.50m)
• Onboarded a record number of new customers and distributors
• Current trading very strong with a record order book
• Outlook for 2025 and beyond remains positive 

Post period-end

• Major new supply agreement in the Far East signed with Kemin China Technology
• Long-term business relationship secured in South Korea with TopHealth
• Launches of YourBiotixMH & PMH – new menopause and post menopause formulations for women’s health
  

Investor Presentation

The Company is hosting a presentation for investors via the Investor Meet Company platform today at 10:00 am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard, up until 9:00 am BST today, or at any time during the live presentation.  

To sign up to the presentation via Investor Meet Company please register using the following link: https://www.investormeetcompany.com/probiotix-health-plc/register-investor 

Steen Andersen, CEO of ProBiotix Health, commented: “The current year has started strongly, with a record order book, significantly ahead of 2024. The robustness of the sales project pipeline has increased further with new product launches planned this year in North America and Europe. We feel confident about the continuing positive development of the Company in 2025, enabling a move to reach break-even. 

We also continue to increase our commercial efforts within Europe, whilst keeping a strategic focus on key potential new markets. We look forward to building on the success of 2024 towards our strategic targets of £10m turnover in 2028 with £2m EBITDA and thank investors for their investment and continued belief in the management team.”

For further information, please contact: 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. 

Notes to Editors: 

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.  

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.